Speedel leads with $56M for Phase III
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Speedel
|
$56 million
|
|
The proceeds from this latest round will be used for clinical pipeline development, specifically for the Phase III study of SPP301. |
|
Tengion
|
$39 million
|
Oak Investment Partners |
Its lead products are organs and tissues derived from a patient's own cells that can be used to replace the patient's diseased or impaired organ or tissues. |
|
Aureon Laboratories
|
$20 million
|
Atlas Venture, Sprout Group |
Aureon has been developing the Prostate Px, a predictive test that will provide urologists with insight into a patient's chance of developing a cancer recurrence following the removal of the prostate. |
|
Intercytex
|
12M sterling
|
Avlar BioVentures |
The financing will be used to complete Phase III trials of ICX-PRO, Intercytex' active woundcare product, take ICX-TRC, its hair regeneration product, through later stage clinical trials and to move ICX-SKN, a living skin replacement, into the clinic. |
|
Oxford Immunotec
|
7M sterling
|
Prelude Ventures |
The money will extend marketing of its first product, a test for tuberculosis. |